Classic Kaposi's sarcoma in morocco: clinico -epidemiological study at the national institute of oncology

BMC Family Practice

Ghizlane Rais¹  Hind Mrabti¹  Fadoi Rais¹  Soundouss Raissouni¹  Narjisse Berrada¹  Hassan Errihani¹ 

[1] Medical oncology department, National Institute of Oncology, Rabat, Morocco

关键词: HHV-8;    clinical features;    Morocco;    CKS;   

Others  :  855314
DOI  :  10.1186/1471-5945-11-15

 received in 2011-05-23, accepted in 2011-11-11,  发布年份 2011

【 摘 要 】

Background

Classic Kaposi's sarcoma (CKS) is a rare disease likely associated with human herpes virus 8 (HHV-8) infection, and occurs predominantly in Jewish, Mediterranean and middle eastern men .There is a dearth of data in Moroccan patients with CKS regarding epidemiology, clinical characteristics and outcomes. This report examines a cohort of patients with CKS evaluated at the national institute of oncology over 11-year period.

Methods

A retrospective analysis of patients referred to the national institute of oncology with classical Kaposi sarcoma, between January 1998 and February 2008, was performed. Reviewed information included demographics, clinical and pathological staging, death or last follow-up.

Results

During the study period, 56 patients with a diagnosis of CKS have been referred to our hospital. There were 11(19,7%) females and 45 (80,3%) males (male-to-female ratio: 4:1). Mean age at diagnosis was 61,7 ± 15 (range: 15- 86 years). Nodules and/or plaques were the most frequent type of lesion. The most common location was the lower limbs, particularly the distal lower extremity (90%). In addition to skin involvement, visceral spread was evident in 9 cases. The most common visceral involvement sites were lymph nodes (44%), lung (22%), and gastrointestinal tract (22%). Associated lymphoedema was seen in 24 (42%) of the patients. There were 18 stage I patients (32,14%), 8: stage II (14,28%), 21 stage III(37,5%) and 9 stage IV (16,07%). A second primary malignancy was diagnosed in 6 cases (10,7%), none of the reticuloendothelial system.

With a median follow-up of 45 months, 38 (67,8) patients are alive, of whom 25 (65,78%) patients with stable disease, five with progressive disease currently under systemic chemotherapy and 8(21,05%) are alive and free of disease, over a mean interval of 5 years.

Conclusion

This is the largest reported series in our context. In Morocco, CKS exhibits some special characteristics including a disseminated skin disease at diagnosis especially in men, a more common visceral or lymph node involvement and a less frequent association with second malignancies.

【 授权许可】

   
2011 Errihani et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Giuseppe Di Lorenzo Update on classic Kaposi sarcoma therapy: New look at an old disease. Critical Reviews in Oncology/Hematology 2008, 68:242-249.
• [2]Schwartz RA: Kaposi's sarcoma: an update. Journal of Surgical Oncology 2004, 87:146-151.
• [3]Noel JC, Hermans P, Andre J, Fayt I, Simonart T, Verhest A, et al.: Herpesvirus-like DNA sequences and Kaposi sarcoma. Relationship with epidemiology, clinical spectrum, and histologic features. Cancer 1996, 77:2132-2136.
• [4]Boschoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, et al.: Kaposi sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995, 1:1274-1278.
• [5]Brambilla L, Boneschi V, Taglioni M, Ferrucci S: Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol 2003, 13:83-6.
• [6]Kaloterakis A, Papasteriades C, Filiotou A, et al.: Hla in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece. Tissue Antigens 1995, 45:117-119.
• [7]Kaposi M: Idiopathisches multiples pigmentsarom der haut. Arch f Dermatol u Syph 1872, 3:265-273.
• [8]Guttman-Yassky E, Bar-Chana M, Yukelson A, Linn S, Friedman- Birnbaum R, Bergman R, et al.: Epidemiology of classic Kaposi's sarcoma in the Israeli Jewish population between 1960 and 1998. Br J Cancer 2003, 89:1657-60.
• [9]Wahman A, Melnick SL, Rhame FS: The epidemiology of classic, African and immunosupressed Kaposi's sarcoma. Epidemiol Rev 1991, 13:178-199.
• [10]Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R: Classic Kaposi sarcoma: epidemiology and risk factors. Cancer 2000, 88:500-17.
• [11]Chang Y, Cesarman E, Pessin MS: Identification of herpes-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1865-1869.
• [12]Schwartz RobertA, Kaposi sarcoma: A continuing conundrum. j am acad dermatol 2008., 59(2)
• [13]Foster CB, Lehrnbecher T, Samuels S, et al.: An IL-16 promoter polymorphism is associated with a lifetime risk of development of Kaposi's sarcoma in men infected with the human immunodeficiency virus. Blood 2000, 96:2562-2567.
• [14]Cassoni P, Sapino A, Deaglio S, et al.: Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross talk. Cancer Res 2002, 62:2406-2413.
• [15]Samaniego F, Gallo RC: Immunopathogenesis of Kaposi's sarcoma. In Immunology of HIV infection. Edited by Gupta S. New York, NY: Plenum Publishing Corp; 1996:437-450.
• [16]Barillari G, Buonaquro L, Fiorelli V, et al.: Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992, 149:3727-3734.
• [17]El Kassimi B: Maladie de Kaposi et anticorps anti-herpès virus-8 au Maroc Médecine et maladies infectieuses. 2003, 33:226-228. John D
• [18]Stratigos , Potouridou Irene, Katoulis AlexanderC, Hatziolou Eftichia, Christofidou Eleftheria, Stratigos Alexander, Hatzakis Angelos, Stavrianeas NicholasG: Classic Kaposi's sarcoma in Greece: a clinico-epidemiologicai profile. International Journai of Dermatology 1997, 36:735-740.
• [19]Einesmith TH, Shrum JP: Kaposi's sarcoma. Int Journal Dermatol 1994, 33:755-62.
• [20]Safai B: Kaposi's sarcoma: a review of the classical and epidemic forms. Ann NY Acad Sci 1984, 437:378-82.
• [21]Di Lorenzo G, Kreuter A, Di Trolio R, et al.: Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol 2008, 128:1578-80.
• [22]Dutz W, Stout AP: Kaposi's sarcoma in infants and children. [Review on the subject of over 1,200 cases up to 1958]. Cancer 1960, 13:684-94.
• [23]Iscovich J, Boffetta P, Brennan P: Classic Kaposi's sarcoma in Arabs living in Israel, 1970-1993: a population-based incidence study. Int J Cancer 1998, 77:319-21.
• [24]Iscovich J, Boffetta P, Winkelmann R, Brennan P, Azizi E: Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. AIDS 1998, 12:2067-72.
• [25]Garcia A, Olivella E, Valderrama S, Rodriguez G: Kaposi's sarcoma in Golombia. Cancer 1989, 64:2393-8.
• [26]Lospalluti M, Mastrolonardo M, Loconsole E, et al.: Glassical Kaposi's sarcoma: a survey of 163 cases observed in Bari, south Italy. Dermatology 1995, 191:104-8.
• [27]Wahman A, Melnick SL, Rhame FS: The epidemiology of classic, African and immunosuppressed Kaposi's sarcoma. Epidemiol Rev 1991, 13:178-199.
• [28]Montesu M, Rossella M, Cottoni F: Le sedi nel sarcoma di Kaposi classico. Studio su una casistica di 200 pazienti [in Italian]. G Ital Dermatol Venereol 1998, 133:247-50.
• [29]Schwartz RA: Kaposi's sarcoma: advances and perspectives. J Am Acad Dermatol 1996, 34:804-14.
• [30]Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al.: Update on Kaposi's sarcoma and othe HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002, 2:281-92.
• [31]Helm F, Burgess G: Kaposi's hemorrhagic sarcoma. In Cancer Dermatology. Edited by Helm F. Philadelphia: Lea &c Febiger; 1979:177-84.
• [32]Kolios G, Kaloterakis A, Filiotou A, Nakos A, Hadziyannis S: Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). Gastrointest Endosc 1995, 42:336-9.
• [33]Cox FH, Helwig EB: Kaposi's sarcoma. Cancer 1959, 12:289-98.
• [34]Iscovich J, Boffetta P, Brennan P: Classic Kaposi's sarcoma as a first primary neoplasm. Int J Cancer 1999, 80:173-177.
• [35]Sapienza G, Nasca MR, Dinotta F, Micali G: Guess what. Classic Kaposi's sarcoma. Eur J Dermatol 2001, 11:157-8.
• [36]Brenner B, Weissmann-Brenner A, Rakowsky E, Weltfriend S, Fenig E, Friedman-Birnbaum R, et al.: Classical Kaposi sarcoma: prognostic factor analysis of 248 patients. Cancer 2002, 95:1982-7.
• [37]Krigel RL, Laubenstein LJ, Mucigia FM: Kaposi's sarcoma: a new staging classification. Cancer Treat Rep 1983, 67:531-534.
• [38]Mitsuyasu RT, Groopman JE: Biology and therapy of Kaposi's sarcoma. Semin Oncol 1984, 11:53-59.
• [39]Giraldo F, Beth F, Huang ES, et al.: Kaposi's sarcoma and its relationship to cytomegalovirus (GMV) III: GMV .1 DNA and early antigens in Kaposi's sarcoma./nZ/-.r'. Cancer 1980, 26:23-9.
• [40]Hiatt KimM, Nelson AnnM, Lichy JackH, Fanburg-Smith JulieC: Classic Kaposi Sarcoma in the United States over the last two decades: Aclinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Modern Pathology 2008, 21:572-582.
• [41]Caccialanza M, Marca S, Piccinno R, Eulisse G: Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. JEADV 2008, 22:297-302.
• [42]Bonnet F, Morlat P: Cancers et infection par le VIH: quelles associations ? La Revue de médecine interne 2006, 27:227-235.
• [43]Feurman EJ, Portruch-Eisenkraft S: Kaposi's sarcoma. Dermatologica 1973, 146:115-122.
• [44]Fenig E, Brenner B, Rakowsky E, et al.: Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol 1998, 21:498-500.
• [45]Digiovana JJ, Safai B: Kaposi's sarcoma: a retrospective study of 90 cases with particular emphasis on the familial occurence, ethnic background and prevalence of other diseases. Am J Med 1981, 71:779-782.
• [46]Lothe F: Kaposi's sarcoma in Ugandian Africans. ACTA Pathol Microbiol Scand 1963, 161(Suppl.):1-71.
• [47]Perniciaro C, Gross DJ, White JW, et al.: Familial Kaposi's sarcoma. Cutis 1996, 57:220-2222.
• [48]Dupin N: Maladie de Kaposi Rev M&d Interne. 1995, 16:484-486.